SoundBite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014 platform in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified below-the-knee (BTK) chronic total occlusions (CTO).
The procedures were performed by Professor Marianne Brodmann, Head of the Clinical Division of Angiology, Department of Internal Medicine, and PD Dr Rief at the Medical University of Graz, Austria. Vascular calcium poses a major challenge for the endovascular treatment of lesions. Our early experience with the 0.014 platform of the SoundBite Crossing System in 5 patients with calcific BTK CTOs shows impressive crossing efficacy and handling with no procedural complications, including perforations, early recoil, or distal embolization in this difficult-to-treat patient population. The SoundBite technology holds promise to significantly transform the treatment of calcified vascular occlusions in patients with peripheral artery disease, commented Dr. Brodmann, MD.
Calcification and CTO encounter is increasingly common in patients with peripheral artery disease (PAD) and CLI and represent important independent predictors of failure for current endovascular device strategies. The leading failure modality in PAD and CLI (especially BTK) interventions remains the inability to cross calcific CTOs and to enter into the true Lumen. CLI, a severe form of PAD, is a life-threatening condition associated with significant morbidity and mortality. Within the first year of CLI diagnosis, 25% of patients die and 30% will have a major limb amputation. Successful revascularization significantly reduces the need for amputations.
There is significant unmet need for devices to safely and easily prepare calcified vessels in patients with occlusive peripheral vascular disease in general, and in patients with BTK disease in particular. We are encouraged by this early experience and are committed to bringing our technology to clinically enhance the way we tackle CTOs and complex calcified cases in this undertreated and challenging patient population, commented Lori Chmura, President and CEO of SoundBite.
The SoundBite Crossing System “ Peripheral (SBCS-P) is a unique and novel first-in-class wire-based active device (Active Wires) for crossing CTOs. SBCS-P leverages SoundBites proprietary method to produce and safely deliver shock waves via guidewire platforms to selectively ˜micro-jackhammer through calcified lesions. SMPS-P is CE marked and available in both 0.018 and 0.014 platforms; the 0.018 platform has also FDA (510k) and Health Canada approvals.
About SoundBite Medical Solutions
SoundBite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. SoundBite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of guidewire-based devices to improve and transform the standard of care for treatment of patients suffering from calcified and occlusive cardiovascular disease. www.soundbitemedical.com
For information on SoundBite Medical Solutions, please contact Ashkan Haghighat (email@example.com), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Qubec H4S 2A4
Forward-Looking Statements This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our managements belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as may, will, should, could, would, outlook, believe, plan, envisage, anticipate, expect and estimate or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.
Ashkan Haghighat, firstname.lastname@example.org